How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Tezepelumab for treating severe asthma

    Closed for comments This consultation ended on at   Request commenting lead permission

    2 Information about tezepelumab

    Marketing authorisation indication

    2.1 Tezepelumab (Tezspire, AstraZeneca) is indicated as 'an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment'.

    Dosage in the marketing authorisation

    2.2 The dosage schedule will be available in the summary of product characteristics for tezepelumab.

    Price

    2.3 The list price for tezepelumab is £1,265 per 210 mg prefilled syringe per vial (company submission, May 2022). The company has a commercial arrangement, which would have applied if tezepelumab had been recommended.